Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2012, Article ID 640815, 9 pages
http://dx.doi.org/10.1155/2012/640815
Review Article

Understanding and Prevention of “Therapy-” Induced Dyskinesias

Unit of Functional Neurosurgery Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London WC1N3BG, UK

Received 12 September 2011; Revised 9 March 2012; Accepted 26 March 2012

Academic Editor: Anna Rosa Carta

Copyright © 2012 Iciar Aviles-Olmos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Ahlskog and M. D. Muenter, “Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature,” Movement Disorders, vol. 16, no. 3, pp. 448–458, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Schrag and N. Quinn, “Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study,” Brain, vol. 123, part 11, pp. 2297–2305, 2000. View at Google Scholar · View at Scopus
  3. V. C. Anderson, K. J. Burchiel, P. Hogarth, J. Favre, and J. P. Hammerstad, “Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease,” Archives of Neurology, vol. 62, no. 4, pp. 554–560, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. K. J. Burchiel, V. C. Anderson, J. Favre, and J. P. Hammerstad, “Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study,” Neurosurgery, vol. 45, no. 6, pp. 1375–1384, 1999. View at Google Scholar · View at Scopus
  5. C. R. Freed, P. E. Greene, R. E. Breeze et al., “Transplantation of embryonic dopamine neurons for severe Parkinson's disease,” New England Journal of Medicine, vol. 344, no. 10, pp. 710–719, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. C. W. Olanow, C. G. Goetz, J. H. Kordower et al., “A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease,” Annals of Neurology, vol. 54, no. 3, pp. 403–414, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. C. B. Lücking, A. Dürr, V. Bonifati et al., “Association between early-onset Parkinson's disease and mutations in the parkin gene,” New England Journal of Medicine, vol. 342, no. 21, pp. 1560–1567, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. N. L. Khan, E. Graham, P. Critchley et al., “Parkin disease: a phenotypic study of a large case series,” Brain, vol. 126, no. 6, pp. 1279–1292, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. L. A. Smith, M. J. Jackson, M. J. Hansard, E. Maratos, and P. Jenner, “Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure,” Movement Disorders, vol. 18, no. 5, pp. 487–495, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. J. G. Nutt, J. A. Obeso, and F. Stocchi, “Continuous dopamine-receptor stimulation in advanced Parkinson's disease,” Trends in Neurosciences, vol. 23, no. 10, pp. S109–S115, 2000. View at Google Scholar · View at Scopus
  11. M. M. Mouradian, J. L. Juncos, G. Fabbrini, and T. N. Chase, “Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies,” Annals of Neurology, vol. 22, no. 4, pp. 475–479, 1987. View at Google Scholar · View at Scopus
  12. D. Nyholm, H. Askmark, C. Gomes-Trolin et al., “Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets,” Clinical Neuropharmacology, vol. 26, no. 3, pp. 156–163, 2003. View at Publisher · View at Google Scholar
  13. E. Bezard, J. M. Brotchie, and C. E. Gross, “Pathophysiology of levodopa-induced dyskinesia: potential for new therapies,” Nature Reviews Neuroscience, vol. 2, no. 8, pp. 577–588, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Rodríguez, P. Barroso-Chinea, P. Abdala, J. Obeso, and T. González-Hernández, “Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in Parkinson's disease,” Experimental Neurology, vol. 169, no. 1, pp. 163–181, 2001. View at Publisher · View at Google Scholar
  15. M. Kuoppamäki, G. Al-Barghouthy, M. J. Jackson, L. A. Smith, N. Quinn, and P. Jenner, “L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates,” Journal of Neural Transmission, vol. 114, no. 9, pp. 1147–1153, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Wichmann and M. R. DeLong, “Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder,” Annals of the New York Academy of Sciences, vol. 991, pp. 199–213, 2003. View at Google Scholar · View at Scopus
  17. I. J. Mitchell, S. Boyce, M. A. Sambrook, and A. R. Crossman, “A 2-deoxyglucose study of the effects of dopamine agonists on the Parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia,” Brain, vol. 115, part 3, pp. 809–824, 1992. View at Google Scholar · View at Scopus
  18. L. V. Laitinen, A. T. Bergenheim, and M. I. Hariz, “Ventroposterolateral pallidotomy can abolish all parkinsonian symptoms,” Stereotactic and Functional Neurosurgery, vol. 58, no. 1–4, pp. 14–21, 1992. View at Publisher · View at Google Scholar · View at Scopus
  19. F. Alonso-Frech, I. Zamarbide, M. Alegre et al., “Slow oscillatory activity and levodopa-induced dyskinesias in Parkinson's disease,” Brain, vol. 129, no. 7, pp. 1748–1757, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Lee, W. M. Zhu, D. Stanic et al., “Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia,” Brain, vol. 131, no. 6, pp. 1574–1587, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Melamed, F. Hefti, and D. J. Pettibone, “Aromatic L-amino acid decarboxylase in rat corpus striatum: Implications for action of L-dopa in parkinsonism,” Neurology, vol. 31, no. 6, pp. 651–655, 1981. View at Google Scholar · View at Scopus
  22. K. Y. Ng, T. N. Chase, R. W. Colburn, and I. J. Kopin, “L-Dopa-induced release of cerebral monoamines,” Science, vol. 170, no. 3953, pp. 76–77, 1970. View at Google Scholar · View at Scopus
  23. M. Carta, T. Carlsson, A. Muñoz, D. Kirik, and A. Björklund, “Involvement of the serotonin system in l-dopa-induced dyskinesias,” Parkinsonism and Related Disorders, vol. 14, supplement 2, pp. S154–S158, 2008. View at Publisher · View at Google Scholar
  24. M. Carta, T. Carlsson, A. Muñoz, D. Kirik, and A. Björklund, “Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias,” Progress in Brain Research, vol. 172, pp. 465–478, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Tanaka, K. Kannari, T. Maeda, M. Tomiyama, T. Suda, and M. Matsunaga, “Role of serotonergic neuron in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats,” Neuroreport, vol. 10, no. 3, pp. 631–634, 1999. View at Google Scholar · View at Scopus
  26. H. S. Lindgren, D. R. Andersson, S. Lagerkvist, H. Nissbrandt, and M. A. Cenci, “L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia,” Journal of Neurochemistry, vol. 112, no. 6, pp. 1465–1476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Carta, T. Carlsson, D. Kirik, and A. Björklund, “Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats,” Brain, vol. 130, no. 7, pp. 1819–1833, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. A. Cenci and M. Lundblad, “Post-versus presynaptic plasticity in L-DOPA-induced dyskinesia,” Journal of Neurochemistry, vol. 99, no. 2, pp. 381–392, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Rylander, M. Parent, S. S. O'Sullivan et al., “Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia,” Annals of Neurology, vol. 68, no. 5, pp. 619–628, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Lee, P. Seeman, A. Rajput, I. J. Farley, and O. Hornykiewicz, “Receptor basis for dopaminergic supersensitivity in Parkinson's disease,” Nature, vol. 273, no. 5657, pp. 59–61, 1978. View at Google Scholar · View at Scopus
  31. H. Shinotoh, K. Hirayama, and Y. Tateno, “Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET.,” Advances in Neurology, vol. 60, pp. 488–493, 1993. View at Google Scholar · View at Scopus
  32. I. Aubert, C. Guigoni, K. Håkansson et al., “Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia,” Annals of Neurology, vol. 57, no. 1, pp. 17–26, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Guigoni and E. Bezard, “Involvement of canonical and non-canonical D1 dopamine receptor signalling pathways in L-dopa-induced dyskinesia,” Parkinsonism and Related Disorders, vol. 15, supplement 3, pp. S64–S67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. A. Berthet, G. Porras, E. Doudnikoff et al., “Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia,” Journal of Neuroscience, vol. 29, no. 15, pp. 4829–4835, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Guigoni, E. Doudnikoff, Q. Li, B. Bloch, and E. Bezard, “Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates,” Neurobiology of Disease, vol. 26, no. 2, pp. 452–463, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Bézard, S. Ferry, U. Mach et al., “Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function,” Nature Medicine, vol. 9, no. 6, pp. 762–767, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. N. P. Visanji, S. H. Fox, T. Johnston, G. Reyes, M. J. Millan, and J. M. Brotchie, “Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease,” Neurobiology of Disease, vol. 35, no. 2, pp. 184–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. R. A. Hauser, O. Rascol, A. D. Korczyn et al., “Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa,” Movement Disorders, vol. 22, no. 16, pp. 2409–2417, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Calabresi, M. di Filippo, V. Ghiglieri, and B. Picconi, “Molecular mechanism underlying levodopa-induced dyskinesia,” Movement Disorders, vol. 23, supplement 3, pp. S570–S579, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. M. di Filippo, B. Picconi, M. Tantucci et al., “Short-term and long-term plasticity at corticostriatal synapses: implications for learning and memory,” Behavioural Brain Research, vol. 199, no. 1, pp. 108–118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Linazasoro, “New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity,” Trends in Pharmacological Sciences, vol. 26, no. 8, pp. 391–397, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Picconi, D. Centonze, K. Håkansson et al., “Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia,” Nature Neuroscience, vol. 6, no. 5, pp. 501–506, 2003. View at Google Scholar · View at Scopus
  43. P. Calabresi, F. Galletti, E. Saggese, V. Ghiglieri, and B. Picconi, “Neuronal networks and synaptic plasticity in Parkinson's disease: beyond motor deficits,” Parkinsonism and Related Disorders, vol. 13, supplement 3, pp. S259–S262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. T. N. Chase, “Striatal plasticity and extrapyramidal motor dysfunction,” Parkinsonism and Related Disorders, vol. 10, no. 5, pp. 305–313, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Ueki, T. Mima, M. A. Kotb et al., “Altered plasticity of the human motor cortex in Parkinson's disease,” Annals of Neurology, vol. 59, no. 1, pp. 60–71, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. F. Morgante, A. J. Espay, C. Gunraj, A. E. Lang, and R. Chen, “Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias,” Brain, vol. 129, no. 4, pp. 1059–1069, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Picconi, V. Paillé, V. Ghiglieri et al., “L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation,” Neurobiology of Disease, vol. 29, no. 2, pp. 327–335, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. T. N. Chase, F. Bibbiani, and J. D. Oh, “Striatal glutamatergic mechanisms and extrapyramidal movement disorders,” Neurotoxicity Research, vol. 5, no. 1-2, pp. 139–145, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. M. A. Cenci, C. S. Lee, and A. Björklund, “L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA,” European Journal of Neuroscience, vol. 10, no. 8, pp. 2694–2706, 1998. View at Publisher · View at Google Scholar · View at Scopus
  50. E. Luginger, G. K. Wenning, S. Bösch, and W. Poewe, “Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease,” Movement Disorders, vol. 15, pp. 873–878, 2000. View at Google Scholar
  51. L. Verhagen Metman, P. del Dotto, P. van den Munckhof, J. Fang, M. M. Mouradian, and T. N. Chase, “Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease,” Neurology, vol. 50, no. 5, pp. 1323–1326, 1998. View at Google Scholar · View at Scopus
  52. L. V. Metman, P. del Dotto, K. LePoole, S. Konitsiotis, J. Fang, and T. N. Chase, “Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study,” Archives of Neurology, vol. 56, no. 11, pp. 1383–1386, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. J. H. Kordower, T. B. Freeman, E. Y. Chen et al., “Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease,” Movement Disorders, vol. 13, no. 3, pp. 383–393, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. O. Lindvall, “Update on fetal transplantation: the Swedish experience,” Movement Disorders, vol. 13, supplement 1, pp. 83–87, 1998. View at Google Scholar · View at Scopus
  55. P. Hagell, P. Piccini, A. Björklund et al., “Dyskinesias following neural transplantation in Parkinson's disease,” Nature Neuroscience, vol. 5, no. 7, pp. 627–628, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. C. W. Olanow, J. M. Gracies, C. G. Goetz et al., “Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in parkinson's disease: a double blind video-based analysis,” Movement Disorders, vol. 24, no. 3, pp. 336–343, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Piccini, N. Pavese, P. Hagell et al., “Factors affecting the clinical outcome after neural transplantation in Parkinson's disease,” Brain, vol. 128, no. 12, pp. 2977–2986, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. R. A. Hauser, T. B. Freeman, B. J. Snow et al., “Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease,” Archives of Neurology, vol. 56, no. 2, pp. 179–187, 1999. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Ma, A. Feigin, V. Dhawan et al., “Dyskinesia after fetal cell transplantation for parkinsonism: a PET study,” Annals of Neurology, vol. 52, no. 5, pp. 628–634, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Boyce, N. M. J. Rupniak, M. J. Steventon, and S. D. Iversen, “Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys,” Clinical Neuropharmacology, vol. 13, no. 5, pp. 448–458, 1990. View at Google Scholar · View at Scopus
  61. C. S. Lee, M. A. Cenci, M. Schulzer, and A. Björklund, “Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease,” Brain, vol. 123, part 7, pp. 1365–1379, 2000. View at Google Scholar · View at Scopus
  62. J. L. Hudson, A. Hoffman, I. Strömberg, B. J. Hoffer, and J. W. Moorhead, “Allogeneic grafts of fetal dopamine neurons: behavioral indices of immunological interactions,” Neuroscience Letters, vol. 171, no. 1-2, pp. 32–36, 1994. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Shinoda, J. L. Hudson, I. Stromberg, B. J. Hoffer, J. W. Moorhead, and L. Olson, “Allogeneic grafts of fetal dopamine neurons: immunological reactions following active and adoptive immunizations,” Brain Research, vol. 680, no. 1-2, pp. 180–195, 1995. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Hagell and M. A. Cenci, “Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective,” Brain Research Bulletin, vol. 68, no. 1-2, pp. 4–15, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Politis, W. H. Oertel, K. Wu et al., “Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio,” Movement Disorders, vol. 26, no. 11, pp. 1997–2003, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Carlsson, M. Carta, C. Winkler, A. Björklund, and D. Kirik, “Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease,” Journal of Neuroscience, vol. 27, no. 30, pp. 8011–8022, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Carlsson, M. Carta, A. Muñoz et al., “Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration,” Brain, vol. 132, no. 2, pp. 319–335, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Carta, T. Carlsson, A. Muñoz, D. Kirik, and A. Björklund, “Role of serotonin neurons in the induction of levodopa—and graft—induced dyskinesias in Parkinson's disease,” Movement Disorders, vol. 25, 1, pp. S174–S179, 2010. View at Publisher · View at Google Scholar
  69. J. García, T. Carlsson, M. Döbrössy, G. Nikkhah, and C. Winkler, “Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia,” Neurobiology of Disease, vol. 43, no. 3, pp. 576–587, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. E. L. Lane, C. Winkler, P. Brundin, and M. A. Cenci, “The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat,” Neurobiology of Disease, vol. 22, no. 2, pp. 334–345, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Vinuela, P. J. Hallett, C. Reske-Nielsen et al., “Implanted reuptake-deficient or wild-type dopaminergic neurons improve on L-dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease,” Brain, vol. 131, no. 12, pp. 3361–3379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. K. Kannari, H. Shen, A. Arai, M. Tomiyama, and M. Baba, “Reuptake of L-DOPA-derived extracellular dopamine in the striatum with dopaminergic denervation via serotonin transporters,” Neuroscience Letters, vol. 402, no. 1-2, pp. 62–65, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Sershen, A. Hashim, and A. Lajtha, “Serotonin-mediated striatal dopamine release involves the dopamine uptake site and the serotonin receptor,” Brain Research Bulletin, vol. 53, no. 3, pp. 353–357, 2000. View at Publisher · View at Google Scholar · View at Scopus
  74. W. J. Marks Jr., J. L. Ostrem, L. Verhagen et al., “Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial,” The Lancet Neurology, vol. 7, no. 5, pp. 400–408, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. C. W. Christine, P. A. Starr, P. S. Larson et al., “Safety and tolerability of putaminal AADC gene therapy for Parkinson disease,” Neurology, vol. 73, no. 20, pp. 1662–1669, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. B. A. Horger, M. C. Nishimura, M. P. Armanini et al., “Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons,” Journal of Neuroscience, vol. 18, no. 13, pp. 4929–4937, 1998. View at Google Scholar · View at Scopus
  77. J. H. Kordower, C. D. Herzog, B. Dass et al., “Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys,” Annals of Neurology, vol. 60, no. 6, pp. 706–715, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. W. J. Marks Jr., R. T. Bartus, J. Siffert et al., “Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial,” The Lancet Neurology, vol. 9, no. 12, pp. 1164–1172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Luo, M. G. Kaplitt, H. L. Fitzsimons et al., “Subthalamic GAD gene therapy in a Parkinson's disease rat model,” Science, vol. 298, no. 5592, pp. 425–429, 2002. View at Publisher · View at Google Scholar · View at Scopus
  80. P. A. LeWitt, A. R. Rezai, M. A. Leehey et al., “AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial,” The Lancet Neurology, vol. 10, no. 4, pp. 309–319, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. K. S. Bankiewicz, M. Daadi, P. Pivirotto et al., “Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys,” Experimental Neurology, vol. 197, no. 2, pp. 363–372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Sun, G. R. Zhang, L. Kong et al., “Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vector,” Human Gene Therapy, vol. 14, no. 5, pp. 415–424, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. T. Björklund, T. Carlsson, E. A. Cederfjäll, M. Carta, and D. Kirik, “Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease,” Brain, vol. 133, no. 2, pp. 496–511, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. V. Bonifati, E. Fabrizio, R. Cipriani, N. Vanacore, and G. Meco, “Buspirone in levodopa-induced dyskinesias,” Clinical Neuropharmacology, vol. 17, no. 1, pp. 73–82, 1994. View at Google Scholar · View at Scopus
  85. C. W. Olanow, P. Damier, C. G. Goetz et al., “Multicenter, open-Label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study),” Clinical Neuropharmacology, vol. 27, no. 2, pp. 58–62, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. C. G. Goetz, P. Damier, C. Hicking et al., “Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial,” Movement Disorders, vol. 22, no. 2, pp. 179–186, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. K. B. Dupre, K. L. Eskow, G. Negron, and C. Bishop, “The differential effects of 5-HT1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat,” Brain Research, vol. 1158, no. 1, pp. 135–143, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. D. Berg, J. Godau, C. Trenkwalder et al., “AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials,” Movement Disorders, vol. 26, no. 7, pp. 1243–1250, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Bibbiani, J. D. Oh, J. P. Petzer et al., “A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease,” Experimental Neurology, vol. 184, no. 1, pp. 285–294, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Fredduzzi, R. Moratalla, A. Monopoli et al., “Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors,” Journal of Neuroscience, vol. 22, no. 3, pp. 1054–1062, 2002. View at Google Scholar · View at Scopus
  91. R. A. Hauser, L. M. Shulman, J. M. Trugman et al., “Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations,” Movement Disorders, vol. 23, no. 15, pp. 2177–2185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. A. J. Manson, E. Iakovidou, and A. J. Lees, “Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease,” Movement Disorders, vol. 15, no. 2, pp. 336–337, 2000. View at Publisher · View at Google Scholar
  93. T. N. Chase, “Alpha-2A adrenergic antagonistis effects in advanced Parkinson's disease. Rome, Italy: Movement Disorders Congress,” Movement Disorders, vol. 15, no. 2, pp. 336–337, 2000. View at Publisher · View at Google Scholar
  94. A. Berthet and E. Bezard, “Dopamine receptors and L-dopa-induced dyskinesia,” Parkinsonism and Related Disorders, vol. 15, supplement 4, pp. S8–S12, 2009. View at Google Scholar
  95. T. Foltynie, C. Brayne, and R. A. Barker, “The heterogeneity of idiopathic Parkinson's disease,” Journal of Neurology, vol. 249, no. 2, pp. 138–145, 2002. View at Google Scholar · View at Scopus
  96. I. A. Prescott, J. O. Dostrovsky, E. Moro, M. Hodaie, A. M. Lozano, and W. D. Hutchison, “Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients,” Brain, vol. 132, no. 2, pp. 309–318, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. P. Calabresi, N. B. Mercuri, and M. di Filippo, “Synaptic plasticity, dopamine and Parkinson's disease: one step ahead,” Brain, vol. 132, no. 2, pp. 285–287, 2009. View at Publisher · View at Google Scholar · View at Scopus